With a constant eye toward personalized medicine, ApoCell scientists understand not only the importance of discovering and analyzing biomarkers, but the need to customize flow cytometry assays for clients to provide them with the important data they need. ApoCell has integrated multi-parameter flow cytometry into our technology platforms to support translational biomarker clinical studies.
Flow cytometry biomarkers are critical in immuno-oncology
The ability to quantify the frequency of specific subpopulations accurately is a key endpoint in immuno-oncology clinical trials. Standardized panels are often very general and not specific enough to capture your subpopulations of interest. ApoCell’s team has the experience and know-how to detect and quantify the specific cells you want.
Beyond immuno-oncology as well
ApoCell uses flow cytometry to detect and quantify circulating endothelial cells, tumor cells, and their apoptotic status has been shown in several recent studies to be predictive of patients’ clinical outcome and response to therapy.